slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 40,801-40,830
Pages 2,019
Rows per page 30
Component
40,801-40,830 of 60,568
15
The slide uses a case study format to validate the efficacy of the company's AI platform.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
16
The heatmap shows edit distance between pairs of HCDR3 sequences; the table shows specific examples of designed sequences and their binding affinity (-Log10 Kd).Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
43
Absci | Investor Presentation Deck | 48 slidesAbsci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
04
The slide provides a breakdown of shares and conversion ratios related to a merger and concurrent financing.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Setup1 hit
05
The slide uses a pipeline table format to show the progression of various drug candidates (SPY001-SPY230) across discovery, IND-enabling, and clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
17
The slide uses a checkmark/empty circle matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
18
The slide uses a central antibody diagram to annotate specific technical improvements over 1st generation mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
30
The slide uses a table-like layout to represent a drug development pipeline.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
41
The slide uses donut charts to represent remission rates and highlights the safety advantages of gut-selective backbones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
48
The slide uses a table-based timeline structure to map specific drug candidates (SPY001-004) to expected regulatory and clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
05
Includes footnotes regarding arbitration and product definitions.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
06
The table includes a blue box highlighting the Q2 2023 column. Footnotes explain the impact of an arbitration settlement on Manufacturing & Royalty Revenue.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
07
Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
15
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
16
The table includes specific line items for share-based compensation, depreciation, amortization, separation expenses, tax effects, non-cash interest, and a significant Janssen arbitration award.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
08
The table displays mean (SD) or n (%) for various clinical metrics including age, gender, diagnosis duration, and disease activity scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
11
The table includes hazard ratios, p-values, and mean changes from baseline for CIDP disease progression and functional scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
12
The slide presents clinical trial safety data for VYVGART Hytrulo.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a waterfall chart to bridge EBITDA performance and a table to bridge to EBT.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
17
The waterfall chart illustrates the bridge between opening and closing cash balances.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
18
The slide includes a footnote regarding rounding and exchange rates.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
22
Includes a table of financial metrics, two donut charts showing shareholder composition, and a bar chart showing net leverage ratio.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations 1 hit